COVID-19 Vaccine (BNT162b2) Trial
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
University Hospitals is a clinical investigational site that is collectively enrolling participants in the BNT162b2 COVID-19 vaccine study. This vaccine is one of the most advanced candidates in the BNT162 program currently being evaluated in the United States and Germany. The Phase 2/3 trial is designed as a 1:1 investigational vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review for this unique vaccine development approach. This vaccine uses mRNA packaged with the coronavirus spike protein to generate protective antibodies and T-cell responses.
This study is currently closed to enrollment.